Leaflet AIRBUFO FORSPIRO 320mcg / 9mcg single-dose inhalation powder

Indicated for: asthma; chronic obstructive pulmonary disease

Route of administration: inhalation

Substance: budesonide + formoterol (glucocorticoid + beta-2 adrenergic agonist)

ATC: R03AK07 (Respiratory system | Adrenergics, inhalants | Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics)

The combination of budesonide and formoterol is used to treat asthma and chronic obstructive pulmonary disease (COPD). It combines a corticosteroid (budesonide) with a long-acting bronchodilator (formoterol), providing both inflammation control and airway relaxation.

Budesonide reduces airway inflammation, preventing asthma symptoms such as wheezing, coughing, and breathing difficulties. Formoterol acts quickly and long-term to relax airway muscles, making breathing easier and preventing asthma attacks.

This combination is used both as maintenance therapy and, in some cases, for the relief of acute symptoms. It is recommended for patients who require both long-term inflammation control and an effective bronchodilator.

Side effects may include dry mouth, throat irritation, hoarseness, tremors, or palpitations. In rare cases, severe allergic reactions, oral fungal infections (thrush), or worsening respiratory symptoms may occur. It is important for patients to rinse their mouth after using the inhaler to prevent oral infections.

Patients should strictly follow their doctor’s instructions regarding inhaler use. It is essential not to exceed the prescribed dose and to use the medication as part of the treatment plan to prevent asthma or COPD exacerbations.